Oikonomou Kyriakos, Pfister Karin, Kasprzak Piotr M, Schierling Wilma, Betz Thomas, Sachsamanis Georgios
Department of Vascular and Endovascular Surgery, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Department of Vascular and Endovascular Surgery, Cardiovascular Surgery Clinic, University Hospital Frankfurt and Johann Wolfgang Goethe University Frankfurt, 60596 Frankfurt, Germany.
J Clin Med. 2022 Jul 29;11(15):4427. doi: 10.3390/jcm11154427.
To present our experience with various therapeutic approaches for the treatment of secondary aortoenteric fistulas following open and endovascular aortic aneurysm repair.
A retrospective data analysis of patients treated for secondary aortoenteric fistulas in a single vascular institution between January 2005 and December 2018 was performed. Analyzed parameters included patients' demographics, clinical presentation, diagnostic work-up, perioperative data and repair durability during follow-up.
Twenty-three patients with aortoenteric fistulas were treated in the target period. The fistulous connection was located in 21 cases (91.3%) in the duodenum and in two cases (8.7%) in the small intestine. Average time between the initial procedure and detection of the aortoenteric fistula was 69.4 ± 72.5 months. The most common presenting symptom was gastrointestinal bleeding ( = 12, 52.2%), followed by symptoms suggestive of chronic infection ( = 11, 47.8%). Open surgical repair was performed in 19 patients (bridging in 3 patients), and endovascular repair was carried out in two cases and one patient underwent a hybrid operation. One patient underwent abscess drainage due to significant comorbidities. Mean follow-up was 35.1 ± 35.5 months. In-hospital mortality and overall mortality were 43.5% (10/23) and 65.2% (15/23), respectively. Patients presenting with bleeding had a significantly higher perioperative mortality rate in comparison to patients presenting with chronic infection (66.7% (8/12) and 18.2% (2/11), respectively, = 0.019). Patients who underwent stent-graft implantation for control of acute life-threatening bleeding showed significantly better perioperative survival in comparison to patients that were acutely treated with an open procedure (66.6%, (4/6) and 0% (0/6), respectively, = 0.014). Perioperative mortality was also higher for ASA IV patients (71.4%, 5/7), when compared to ASA III Patients (31.2%, 5/16), although this did not reach statistical significance ( = 0.074).
Treatment of secondary aortoenteric fistulas is associated with a high perioperative mortality rate. Patients who survive the perioperative period following open surgical repair in the absence of hemorrhagic shock show acceptable midterm results during follow-up. Stent-graft implantation for bleeding control in patients presenting with life-threatening bleeding seems to be associated with lower perioperative mortality rates.
介绍我们在开放和血管腔内主动脉瘤修复术后继发性主动脉肠瘘的各种治疗方法方面的经验。
对2005年1月至2018年12月期间在单一血管机构接受继发性主动脉肠瘘治疗的患者进行回顾性数据分析。分析参数包括患者的人口统计学、临床表现、诊断检查、围手术期数据以及随访期间修复的耐久性。
在目标期间治疗了23例主动脉肠瘘患者。瘘管连接位于十二指肠21例(91.3%),小肠2例(8.7%)。初次手术至发现主动脉肠瘘的平均时间为69.4±72.5个月。最常见的表现症状是胃肠道出血(n = 12,52.2%),其次是提示慢性感染的症状(n = 11,47.8%)。19例患者进行了开放手术修复(3例为桥接手术),2例进行了血管腔内修复,1例患者接受了杂交手术。1例患者因严重合并症接受了脓肿引流。平均随访时间为35.1±35.5个月。住院死亡率和总死亡率分别为43.5%(10/23)和65.2%(15/23)。与表现为慢性感染的患者相比,表现为出血的患者围手术期死亡率显著更高(分别为66.7%(8/12)和18.2%(2/11),P = 0.019)。与接受开放手术急性治疗的患者相比,接受支架移植物植入以控制急性危及生命出血的患者围手术期生存率显著更好(分别为66.6%(4/6)和0%(0/6),P = 0.014)。与ASA III级患者(31.2%,5/16)相比,ASA IV级患者围手术期死亡率也更高(71.4%,5/7),尽管这未达到统计学意义(P = 0.074)。
继发性主动脉肠瘘的治疗与高围手术期死亡率相关。在没有失血性休克的情况下接受开放手术修复且围手术期存活的患者在随访期间中期结果可接受。对于出现危及生命出血的患者,植入支架移植物控制出血似乎与较低的围手术期死亡率相关。